These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 16567968

  • 1. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines.
    Mayorga ME, Sanchis D, Perez de Santos AM, Velasco A, Dolcet X, Casanova JM, Baradad M, Egido R, Pallares J, Espurz N, Benitez D, Mila J, Malvehy J, Castel T, Comella JX, Matias-Guiu X, Vilella R, Marti RM.
    Melanoma Res; 2006 Apr; 16(2):127-35. PubMed ID: 16567968
    [Abstract] [Full Text] [Related]

  • 2. [In vitro killing effects of STI571 on esophageal carcinoma cell lines CE-48T and CE-81T].
    Zhang PY, Li BJ, Su XD, Wen ZS, Zhao JM, Zhang LJ, Long H, Rong TH.
    Ai Zheng; 2006 Apr; 25(4):456-60. PubMed ID: 16613680
    [Abstract] [Full Text] [Related]

  • 3. Inhibitory effect of STI571 on cell proliferation of human malignant fibrous histiocytoma cell lines.
    Kawamoto T, Akisue T, Marui T, Nakatani T, Hitora T, Fujita I, Kurosaka M, Yamamoto T.
    Anticancer Res; 2004 Apr; 24(5A):2675-9. PubMed ID: 15517872
    [Abstract] [Full Text] [Related]

  • 4. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
    Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB.
    J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
    [Abstract] [Full Text] [Related]

  • 5. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
    Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, Guha A.
    Cancer Res; 2009 Jun 15; 69(12):5099-107. PubMed ID: 19509233
    [Abstract] [Full Text] [Related]

  • 6. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.
    Oncogene; 2006 Dec 07; 25(58):7618-34. PubMed ID: 16983347
    [Abstract] [Full Text] [Related]

  • 7. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D, Niveiro M, Diwan AH, Eton O, Kim KB, Lacey C, Gonzalez C, Prieto VG.
    J Cutan Pathol; 2006 Apr 07; 33(4):280-5. PubMed ID: 16630177
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E, Basso G.
    Int J Mol Med; 2004 Sep 07; 14(3):373-82. PubMed ID: 15289888
    [Abstract] [Full Text] [Related]

  • 12. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM, Broaddus RR, Schmandt R, Wu W, Oh JC, Ramondetta LM, Burke TW, Gershenson DM, Lu KH.
    Gynecol Oncol; 2004 Oct 07; 95(1):32-6. PubMed ID: 15385107
    [Abstract] [Full Text] [Related]

  • 13. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
    Yoshitani K, Honoki K, Morishita T, Kido A, Miyauchi Y, Mii Y, Takakura Y.
    In Vivo; 2003 Oct 07; 17(3):255-8. PubMed ID: 12929576
    [Abstract] [Full Text] [Related]

  • 14. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
    Zhang P, Gao WY, Turner S, Ducatman BS.
    Mol Cancer; 2003 Jan 03; 2():1. PubMed ID: 12537587
    [Abstract] [Full Text] [Related]

  • 15. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A, Zoltan-Jones A, Strizzi L, Bargo S, Kimura K, Salomon D, Callahan R.
    Oncogene; 2007 Feb 01; 26(5):662-72. PubMed ID: 16878155
    [Abstract] [Full Text] [Related]

  • 16. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 Feb 01; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 17. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, André T, Mareel M, Mester J, Gespach C.
    Cancer Res; 2002 Sep 01; 62(17):4879-83. PubMed ID: 12208734
    [Abstract] [Full Text] [Related]

  • 18. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
    Wang-Rodriguez J, Lopez JP, Altuna X, Chu TS, Weisman RA, Ongkeko WM.
    Laryngoscope; 2006 Aug 01; 116(8):1409-16. PubMed ID: 16885745
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.